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Background: The choice of stent used in iliac artery revascularization depends upon the morphology & location of the lesion but otherwise 
evidence to support particular stent design is insufficient. Aim of this meta-analysis was to compare the efficacy and outcomes of various stents 
used in iliac artery revascularization.
Methods: Systematic literature search using key words “iliac artery stent” revealed 38 studies reporting outcomes for a single stent in iliac artery 
revascularization. Data was extracted about following outcomes, major adverse events (MAE), and change in Ankle: Brachial Index (ABI) post stent 
and primary patency rates. A fixed-effect and random effect model was used to calculate endpoints for homogenous and heterogeneous outcomes 
respectively.
Results: Wallstent was associated with lower MAE as compared to Strecker stent (RR = 0.62, p = 0.003) and Palmaz stent (RR = 0.54, p = 0.008) 
but no different than Nitinol stent (RR=1.175, p= 0.412). Wallstent had greater decrease in post stent ABI compared to Palmaz (0.036, p < 0.001) 
and Strecker (0.061, p < 0.001) but no difference compared to Nitinol (0.002, p= 0.267). Primary patency of Wallstent was found to lower as 
compared to Nitinol (RR = 0.89 p < 0.001) and Palmaz (RR = 0.93, p = 0.002) at 1 yr.
Conclusion: Current analysis of available studies suggest newer stents like Wallstent and Nitinol might be slightly better on 
endpoints like adverse events and ABI improvement. Nitinol stent may provide better patency rates then Wallstent at 1 year.
